IDH1/2 mutations can be disease-initiating in CH, although they tend to occur later in life, and often in conjunction with DNMT3A mutations resulting in a synergistic selective advantage [8,28,56]. The gene discussed is DNMT3A; the disease is cyclic hematopoiesis.